MedTrace Logo

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

NCT00043394 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2009-03-12

No results posted yet for this study

Summary

To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients with metastatic breast cancer.

Conditions

  • Carcinoma, Breast

Interventions

DRUG

0.04 mg/kg CpG 7909

0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks

DRUG

Herceptin®

Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.

DRUG

0.08 mg/kg CpG 7909

0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks

DRUG

Herceptin®

Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.

DRUG

0.12 mg/kg CpG 7909

0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks

DRUG

Herceptin®

Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.

DRUG

0.16 mg/kg CpG 7909

0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks

DRUG

Herceptin®

Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2003-10-31
Completion
2003-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00043394 on ClinicalTrials.gov